Dyne Therapeutics, Inc.

DYN

US26818M1080

Biotechnology & Medical Research

Market Closed - Nasdaq 08:00:00 06/11/26 am AEDT			5-day change	1st Jan Change
17.36 ^USD	-6.36%		+1.88%	-11.25%

06/11	Dyne Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
28/10	Oppenheimer Downgrades Dyne Therapeutics to Perform From Outperform, $15 Price Target	MT

Top Premarket Decliners

Published on 09/08/2026 at 09:57 pm AEST

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Dyne Therapeutics, Inc.

06/11	Dyne Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
28/10	Oppenheimer Downgrades Dyne Therapeutics to Perform From Outperform, $15 Price Target	MT
30/09	Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial Of Z-Basivarsen For Myotonic Dystrophy Type 1	CI
20/09	Certain Restricted Stock Units of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026.	CI
20/09	Certain Common Stock of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026.	CI
20/09	Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026.	CI
15/09	Dyne Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 09:15 AM
10/09	Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says	MT
09/09	JPMorgan Downgrades Dyne Therapeutics to Underweight From Neutral, Cuts Price Target to $10 From $17	MT
09/09	RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk	MT
09/09	Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers	RE
08/09	Dyne Therapeutics Presents Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1	CI
08/09	Top Premarket Decliners	MT
31/07	RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk	MT
30/07	Dyne Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Employees

289

Sector

Biotechnology & Medical Research

More about the company